Document is current
Any future updates will be listed below
-
Authors
Finckh, Axel https://orcid.org/0000-0002-1210-4347
Gilbert, Benoît
Hodkinson, Bridget
Bae, Sang-Cheol https://orcid.org/0000-0003-4658-1093
Thomas, Ranjeny https://orcid.org/0000-0002-0518-8386
Deane, Kevin D. https://orcid.org/0000-0003-2211-4861
Alpizar-Rodriguez, Deshiré
Lauper, Kim https://orcid.org/0000-0002-4315-9009
- License Information
-
More Information
Article History
Accepted: 3 August 2022
First Online: 6 September 2022
Competing interests
: A.F. received funding from Abbvie, Bristol Myers Squibb, Galapagos, and Pfizer to the Geneva University Hospital, and consultancy or honoraria from Abbvie, Bristol Myers Squibb, Eli-Lilly, MSD and Pfizer. R.T. received funding from Janssen Biotech to Uniquest (the commercialization company of the University of Queensland), consultancy or honoraria from Bristol Myers Squibb, Abbvie, Janssen, Merck, CSL, Viela Bio and Sandoz, and is a named inventor on patent 9,017,697 B2, relating to compositions and methods for modulating immune responses. K.D.D. received funding for consultancy from Inova Diagnostics, Bristol Myers Squibb and Janssen. D.A.R. is a scientific adviser for GlaxoSmithKline Mexico, unrelated to the topic of this manuscript. K.L. received consultancy or honoraria from Celltrion, Pfizer, Viatris and Galapagos. The other authors declare no competing interests.
